| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 03/15/2023 | Aligos Therapeutics, Inc. | ALGS | Grant | Stock Option (Right to Buy) | 169.5k | $1.34 | $227.1k | | 03/15/2023 |
| 07/07/2022 | Aligos Therapeutics, Inc. | ALGS | Grant | Stock Option (Right to Buy) | 113k | $1.41 | $159.3k | | 07/07/2022 |
| 02/04/2022 | Aligos Therapeutics, Inc. | ALGS | Grant | Stock Option (Right to Buy) | 226.8k | $3.06 | $694k | | 02/04/2022 |
| 02/04/2022 | Aligos Therapeutics, Inc. | ALGS | Grant | Stock Option (Right to Buy) | 56.7k | $3.06 | $173.5k | | 02/04/2022 |
| 12/01/2020 | Aligos Therapeutics, Inc. | ALGS | Grant | Stock Option (Right to Buy) | 300k | $16.18 | $4.9M | | 12/01/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 163.8k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 13.6k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 13.6k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 50.8k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 3.4k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 3.4k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 21.7k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 1.4k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 1.4k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series A Preferred Stock | 163.8k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series A Preferred Stock | 13.6k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series A Preferred Stock | 13.6k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series B-1 Preferred Stock | 50.8k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series B-1 Preferred Stock | 3.4k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series B-1 Preferred Stock | 3.4k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series B-2 Preferred Stock | 21.7k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series B-2 Preferred Stock | 1.4k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series B-2 Preferred Stock | 1.4k | $0.00 | $0 | See footnote | 10/20/2020 |